Literature DB >> 28331982

Autoantibodies in children with juvenile dermatomyositis: A single centre experience from North-West India.

Altaf Hussain1, Amit Rawat2, Ankur Kumar Jindal1, Anju Gupta1, Surjit Singh1.   

Abstract

The objective of this study is to determine autoantibody profile in children with juvenile dermatomyositis (JDM). Children who were diagnosed with JDM (either recently diagnosed during the study period or follow-up patients) were included in the study. Autoantibodies were detected with commercially available Immunodot kit. Thirty patients were included in the study. Nine out of thirty patients (30%) were positive for one of the 12 autoantibodies tested. Anti-SRP antibody was most common antibody detected in 3 patients followed by anti-MDA-5 antibody in 2 patients; while anti-Jo1 antibody, anti-TIF1-γ antibody, anti-Mi-2 antibody, and anti-PM-Scl antibody were positive in 1 patient each. A different disease phenotype was observed with each autoantibody. The patient with anti-Jo1 antibody had a severe systemic disease in the form of interstitial lung disease; patients with anti-MDA-5 antibody and anti-Mi2 antibody had more severe skin disease with mild muscle disease and patients with anti-SRP antibody had significant skin and muscle disease. Anti-TIF1-γ and anti-PM-Scl antibodies were seen in patients with features of overlap syndrome (myositis-scleroderma). Estimation of autoantibodies may serve as an adjunct tool in delineating and defining distinct clinical phenotypes in children diagnosed with juvenile dermatomyositis. They may also help in prognostication.

Entities:  

Keywords:  Anti-Jo1; Anti-MDA-5; Anti-Mi2; Anti-PM-Scl; Anti-SRP; Anti-TIF1-γ; Autoantibody; Juvenile dermatomyositis

Mesh:

Substances:

Year:  2017        PMID: 28331982     DOI: 10.1007/s00296-017-3707-4

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  33 in total

1.  Antibody to signal recognition particle in polymyositis.

Authors:  I N Targoff; A E Johnson; F W Miller
Journal:  Arthritis Rheum       Date:  1990-09

2.  A novel autoantibody to a 155-kd protein is associated with dermatomyositis.

Authors:  Ira N Targoff; Gulnara Mamyrova; Edward P Trieu; Osvaldo Perurena; Bhanu Koneru; Terrance P O'Hanlon; Frederick W Miller; Lisa G Rider
Journal:  Arthritis Rheum       Date:  2006-11

3.  Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota.

Authors:  Margo J Bendewald; David A Wetter; Xujian Li; Mark D P Davis
Journal:  Arch Dermatol       Date:  2010-01

4.  The incidence of juvenile dermatomyositis: results from a nation-wide study.

Authors:  D P Symmons; J A Sills; S M Davis
Journal:  Br J Rheumatol       Date:  1995-08

5.  Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis.

Authors:  H Gunawardena; L R Wedderburn; J North; Z Betteridge; J Dunphy; H Chinoy; J E Davidson; R G Cooper; N J McHugh
Journal:  Rheumatology (Oxford)       Date:  2008-01-30       Impact factor: 7.580

6.  A broadened spectrum of juvenile myositis. Myositis-specific autoantibodies in children.

Authors:  L G Rider; F W Miller; I N Targoff; D D Sherry; E Samayoa; M Lindahl; M H Wener; L M Pachman; P H Plotz
Journal:  Arthritis Rheum       Date:  1994-10

7.  Clinical characteristics of children with juvenile dermatomyositis: the Childhood Arthritis and Rheumatology Research Alliance Registry.

Authors:  Angela Byun Robinson; Mark F Hoeltzel; Dawn M Wahezi; Mara L Becker; Elizabeth A Kessler; Heinrike Schmeling; Ruy Carrasco; Adam M Huber; Brian M Feldman; Ann M Reed
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-03       Impact factor: 4.794

8.  Twelve years experience of juvenile dermatomyositis in North India.

Authors:  Surjit Singh; Arun Bansal
Journal:  Rheumatol Int       Date:  2005-09-15       Impact factor: 3.580

9.  Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study.

Authors:  Sarah L Tansley; Zoe E Betteridge; Harsha Gunawardena; Thomas S Jacques; Catherine M Owens; Clarissa Pilkington; Katie Arnold; Shireena Yasin; Elena Moraitis; Lucy R Wedderburn; Neil J McHugh
Journal:  Arthritis Res Ther       Date:  2014-07-02       Impact factor: 5.156

10.  Redefining dermatomyositis: a description of new diagnostic criteria that differentiate pure dermatomyositis from overlap myositis with dermatomyositis features.

Authors:  Yves Troyanov; Ira N Targoff; Marie-Pier Payette; Jean-Pierre Raynauld; Suzanne Chartier; Jean-Richard Goulet; Josiane Bourré-Tessier; Eric Rich; Tamara Grodzicky; Marvin J Fritzler; France Joyal; Martial Koenig; Jean-Luc Senécal
Journal:  Medicine (Baltimore)       Date:  2014-11       Impact factor: 1.889

View more
  3 in total

1.  Inverse Gottron papules in juvenile dermatomyositis: an under recognized clinical entity.

Authors:  Ankur Kumar Jindal; Sandesh Guleria; Rakesh Kumar Pilania; Anuradha Bishnoi; Keshavamurthy Vinay; Sunil Dogra; Deepti Suri; Amit Rawat; Surjit Singh
Journal:  Rheumatol Int       Date:  2018-05-02       Impact factor: 2.631

2.  Geographical Latitude Remains as an Important Factor for the Prevalence of Some Myositis Autoantibodies: A Systematic Review.

Authors:  Andrea Aguilar-Vazquez; Efrain Chavarria-Avila; Oscar Pizano-Martinez; Alejandra Ramos-Hernandez; Lilia Andrade-Ortega; Edy-David Rubio-Arellano; Monica Vazquez-Del Mercado
Journal:  Front Immunol       Date:  2021-04-22       Impact factor: 7.561

Review 3.  Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry.

Authors:  Pankti Mehta; Pedro M Machado; Latika Gupta
Journal:  Rheumatol Int       Date:  2021-03-27       Impact factor: 2.631

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.